Venom Meets Hub-Proteins: Computational Forecasting of Calloselasma rhodostoma-Derived Peptides Targeting Cancer Network Hubs

The Unconventional Interface: Venom Peptides in Cancer Systems Biology

In the landscape of modern oncology, exploring unconventional molecular sources has become a defining trend. Among these, snake-venom peptides have presented themselves as rich reservoirs of biologically active scaffolds, capable of interacting with cellular machineries in ways that small molecules often cannot. The Malayan pit viper Calloselasma rhodostoma, in particular, produces a venomic repertoire whose peptides have been shown experimentally to perturb integrin-mediated adhesion, migration, and angiogenesis in tumour models. These observations suggest that beyond haemotoxicity, venom peptides may harbour anti-cancer potential by virtue of their ability to interface with key cellular networks. The computational study at hand thus asks: can peptides mined from C. rhodostoma venom be predicted to interact with cancer-associated hub proteins, thereby offering starting points for novel therapeutic leads?

Harnessing this potential demands a shift from classical ligand-target paradigms toward network-aware computational frameworks. Instead of simply docking a peptide to a known receptor site, the question becomes systemic: which hub proteins in oncogenic signalling networks are amenable to binding by venom-derived peptides? These hubs—typically highly connected nodes in protein–protein interaction (PPI) networks—can regulate transcription, signal transduction, and cellular homeostasis. Targeting them with peptides offers both opportunity and risk: greater disruption potential, but also higher sensitivity to off-target and compensatory responses. Here, computational methods offer a way to triage large peptide–protein combinations without exhaustive wet-lab screening.

The work in question applies three predictive algorithms—Random Forest, XGBoost, and a deep neural network pre-trained via stacked autoencoders (SAE-DNN)—to the peptide–protein interaction (PPI) problem. Feature extraction encompasses peptide and protein intrinsic disorder, amino acid composition, dipeptide composition, physicochemical properties, and PSSM (position-specific scoring matrix) profiles. By working from sequence alone, the study bypasses the need for high-resolution structural data, making it accessible to poorly characterised venom peptides and emergent cancer proteins. Validation is completed by enrichment analysis, revealing that predicted interactions focus on hub proteins such as ESR1, GOPC and BRD4—each deeply implicated in cancer biology.

In essence, this computational study does not simply ask whether a given peptide can bind a protein; it asks whether venomic peptides can rewiring key hubs in cancer network architectures. The next sections unpack the methodology, the biological rationale, the computational architecture, the emergent predictions and their implications for therapeutic translation.

Mapping Cancer Hub Proteins and Venom Peptide Candidates

Central to the study is the concept of “hub proteins”: nodes within protein-protein interaction networks that exhibit high connectivity, regulatory influence and often essential functions in cancer biology. ESR1 (estrogen receptor α), for example, sits at the nexus of hormone regulation, transcription control, and tumour progression in breast cancer. Its mutational dysregulation and hormone-therapy resistance make it a compelling target. GOPC (Golgi-associated PDZ and coiled-coil motif-containing protein) regulates receptor trafficking and surface expression, with lower expression correlating with worse prognosis in colorectal cancer. BRD4 (bromodomain-containing protein 4) is a chromatin “reader” that binds acetylated histones, organizes super-enhancers and drives oncogene transcription, making it an epigenetic hub in multiple cancers. The study identifies these proteins as overlapping targets of predicted venom-peptide interactions.

On the opposite side of the equation lie the peptides derived from C. rhodostoma venom. These peptides are typically short, disulfide-rich, and often carry motifs (such as RGD) that mediate integrin binding, and consequently perturb cell adhesion, migration and angiogenesis. Historically, disintegrins from viper venoms have shown anti-tumour potential in vitro and in vivo. In the computational study, the venom peptides were obtained via trypsin digestion of freeze-dried venom followed by mass spectrometry, generating a library of 145 unique peptides for testing against cancer-associated proteins. This sets the stage for peptide–protein pairing across a large combinatorial space.

Feature extraction was conducted on both peptides and target proteins. For proteins, PSSM profiles provide evolutionary conservation information; intrinsic disorder scores describe propensity for unstructured regions; amino acid and dipeptide compositions summarise sequence content; physicochemical indexes capture hydropathy, charge, polarity. Peptides were similarly profiled, albeit with adjustments for shorter length. The sequences were padded or truncated to standard lengths (≤50 or ≤19 for peptides; ≤1500 for proteins) to generate uniform feature vectors. Negative samples (non-interacting peptide–protein pairs) were generated by random shuffling to form a training dataset. This preparation enables machine-learning prediction of whether a given peptide–protein pair is likely to interact.

In this way the study merges venom-biology and cancer biology within a unified computational framework. The hub proteins represent systemic leverage points in oncogenesis, the venom peptides represent untapped molecular space with promiscuous binding potential, and the predictive algorithms mediate their intersection. The outcome is a ranked list of peptide–protein pairs worthy of further experimental validation.

Algorithmic Framework: From Features to Predictions

The study employs three algorithms: Random Forest (RF), XGBoost and a Stacked Autoencoder Deep Neural Network (SAE-DNN). Each algorithm contributes differently to the predictive pipeline, with trade-offs between interpretability, non-linearity handling and feature-selection capacity.

Random Forest is an ensemble tree-based method that builds many decision trees on bootstrapped subsets of the data and aggregates their predictions via majority voting. It handles high-dimensional data and provides implicit feature importance measures, making it a pragmatic choice for the peptide–protein interaction problem where many features may correlate or be redundant. XGBoost (eXtreme Gradient Boosting) is a boosting algorithm that builds trees sequentially to correct previous errors, optimises via first and second derivatives of the loss function, and inherently performs feature routing and selection through gain scoring. XGBoost often outperforms simpler tree-ensembles by capturing more subtle interactions among features. The SAE-DNN method uses stacked autoencoders to pre-train weights in a deep neural network architecture, thus improving weight initialisation and enabling deeper learning of non-linear feature transformations. Once pre-trained, the network is fine-tuned to perform binary classification of peptide–protein interaction vs non-interaction.

Hyperparameters for each algorithm were optimised via Bayesian optimisation or grid search: e.g., number of trees (n_estimators), maximum tree depth, learning rates for boosting, number and sizes of hidden layers, dropout rates for DNN. The study constructed two dataset versions: one with peptide length ≤ 50 and the other with peptide length ≤ 19, to test effect of peptide size. Training used stratified 5-fold cross-validation to balance positive and negative classes and avoid bias. The primary evaluation metrics included accuracy, precision and ROC-AUC (area under the receiver-operating characteristic curve). Though the study mentions recall and F1-score, the interpretive focus remains on accuracy and AUC.

What emerges is that all algorithms perform “reasonably well” in the binary classification task. The XGBoost model achieved the best reported values among the test scenarios. The study emphasises that prediction from sequence alone—without explicit structural docking—is feasible, thereby simplifying the screening of venom-derived peptides. However, the authors also acknowledge limitations: low recall in many models (indicating false negatives), modest generalisation, and inability to pinpoint specific binding residues or structural interfaces. The algorithmic framework thus provides a broad-scale screening tool rather than a detailed molecular mechanism predictor.

In technical terms, the pipeline is robust for high-throughput filtering of peptide–protein space, enabling researchers to prioritise candidate interactions for wet-lab follow-up. It does not replace structural modelling, but it complements it by narrowing the search space.

Emergent Predictions and Biological Implications

The computational screening of ~23,925 venom-peptide/cancer-protein pairs (145 peptides × 165 proteins) revealed overlapping predicted interactions across the models, particularly focusing on three hub proteins: ESR1, GOPC and BRD4. For example, in one scenario the intersection of predicted pairs in datasets versions 1 and 2 yielded 64 unique peptides interacting with those three proteins. Enrichment analysis (via KEGG and GO) on these proteins showed functional links to cancer-related pathways: ESR1 entered signalling pathways for breast cancer and endocrine regulation, BRD4 linked to chromatin regulation and oncogene activation, and GOPC implicated in Golgi-trafficking and membrane-protein homeostasis. The fact that venom peptides may target these hubs raises the possibility of novel mechanism-based therapeutic leads.

From a mechanistic viewpoint, one may hypothesise that venom-derived peptides interact with these hub proteins via multi-valent motifs or fold-rich structures that mimic endogenous regulatory peptides. For instance, BRD4, as a reader of acetylated histones, may present binding grooves or interfaces accessible to small peptides; venom peptides might exploit these. ESR1, being a nuclear hormone receptor, possesses ligand-binding pockets and co-factor interaction domains, which could interface with non-canonical peptides. The model predictions thus open the door to repurposing venom peptides as modulators of transcriptional hubs rather than classical enzyme inhibitors.

Therapeutically, this suggests a paradigm shift: venom peptides are not merely cytotoxins or membrane-disruptors, but potential modulators of intracellular signalling hubs. Their ability to engage multiple peptides per hub (as the model predicts) suggests potential poly-valent binding, network rewiring and combinatorial disruption of cancer networks. Nevertheless, experimental validation remains critical. Predictions must be followed by binding assays, cellular functional assays, toxicity profiling and pharmacokinetic optimisation.

Long-term implications include designing peptide analogues derived from venom sequences but optimised for stability, specificity and cell-penetration. The computational workflow accelerates this by pre-selecting high-likelihood interactions, thereby reducing screening cost. Ultimately, venom-derived peptides may join the class of targeted biologics or peptide-drugs in oncology, leveraging their natural potency and specificity in a more refined therapeutic context.

Limitations, Translational Challenges and Future Directions

Despite the promising angle, the computational study is constrained by several intrinsic limitations which temper the translational enthusiasm. First, the reliance on sequence-based features only means the predicted interactions lack structural resolution. Without docking, molecular dynamics or binding-site annotation, one cannot localise the peptide footprint on the target protein, nor predict dissociation constants or off-target effects. This limits confident progression to mechanistic drug design.

Second, the datasets are modest in scale and imbalanced. The number of positive peptide–protein pairs is relatively small compared to possible negative combinations, and the generated negative samples are randomly sampled rather than experimentally confirmed non-binders. This introduces bias and may result in models that prioritise false positives or false negatives. The low recall observed in several scenarios underscores this issue: many interacting pairs may remain undetected by the model. From a practical standpoint, this means experimentalists must be aware that the pipeline may miss potentially interesting leads.

Third, venom peptides themselves pose translational challenges. Native venom sequences may be unstable in human physiological conditions, immunogenic, poorly bioavailable or exhibit off-target toxicity. Thus, even high-score computational hits require peptide optimisation (e.g., modification of disulfide bonds, cyclisation, pegylation, cell-penetrating motifs) and rigorous toxicology. The computational filter does not evaluate these properties, meaning downstream experimental burden remains significant.

In terms of future directions, several enhancements are plausible. Incorporating structural modelling (e.g., docking, molecular dynamics, binding-site prediction) would provide binding-site resolution and prioritise peptides by binding affinity. Multi-task learning could integrate peptide stability, toxicity and cell-penetration features alongside binding prediction. Expanding the peptide library (for example via venom-transcriptomics or combinatorial peptide libraries) would enhance model generalisation. Finally, integrating network-dynamics simulation could assess how binding of a hub protein by a venom peptide propagates through the cellular interaction network, predicting downstream phenotypic effects (e.g., apoptosis, migration, invasion).

In summary, while the computational study offers a smart and timely pipeline for identifying venom-peptide/cancer-protein interactions, it is an early step on the translational ladder. The path from in silico prediction to clinical therapeutic is long, but the approach presents a strategic vantage point to accelerate discovery.

Study DOI: https://doi.org/10.1016/j.heliyon.2023.e21149

Engr. Dex Marco Tiu Guibelondo, B.Sc. Pharm, R.Ph., B.Sc. CompE

Editor-in-Chief, PharmaFEATURES